Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects

Thorax

Volumn 52, Issue 5, 1997, Pages 458-464

  Bennett, Jon A ^a   Tattersfield, Anne E ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Salbutamol; Salmeterol; Systemic activity

Indexed keywords

SALBUTAMOL; SALMETEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG POTENCY; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030925304     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.5.458     Document Type: Article

References (24)

1. Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Gilliag C. Case control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990;45:170-5.
2. Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, et al. Prescribed fenorerol and death from asthma in New Zealand, 1981-7: a further case control study. Thorax 1991;46:105-11.
3. Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989; i:917-22.
4. Stolley PD. Asthma mortality: why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972;105:883-90.
5. Crane J, Burgess C, Beasley R. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol and isoprenaline. Thorax 1989;44:136-40.
6. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990;336:1396-9.
7. 2 receptor selectivity: a study of metaproterenol, fenoterol, isoproterenol, and epinephrine in patients with asthma. Am Rev Respir Dis 1991;143:444-6.
8. Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M, et al. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 1991;104: 665-71.
9. 2-agonists in lung and heart. Am J Respir Crit Care Med 1996;153:1489-95.
10. Smyth ET, Pavord ID, Wong CS, Wisniewski AF, Williams J, Tattersfield AE. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ 1993;306:543-45.
11. Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994;49:771-4.
12. Finney DJ. Statistical methods in biological assay. London: Griffin, 1964.
13. Maconochie JG, Forster JK. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol 1992;33:342 5.
14. Davies DS. Pharmacokinetics of inhaled substances. Postgrad Med J 1975;51:69 75.
15. Morgan DJ. Clinical pharmacokinetics of beta-agonists. Clin Pharmacokinet 1990;18:270-94.
16. Lipworth BJ, Clark RA, Dhillon DP, Brown RA, McDevitt DG. Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. Br J Clin Pharmacol 1988;26:527-33.
17. 2 activity of inhaled fenoterol in normal subjects. Thorax 1993;48:656-8.
18. Newnham DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax 1994;49:762-70.
19. Dougall IG, Harper D, Jackson DM, Leff P. Estimation of the efficacy and affinity of the beta 2-adrenoceptor agonist salmeterol in guinea-pig trachea. Br J Pharmacol 1991; 104:1057-61.
20. Collier JG, Dobbs RJ, Williams I. Salbutamol aerosol causes a tachycardia due to the inhaled rather than the swallowed fraction. Br J Clin Pharmacol 1980;9:273-4.
21. Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 1986;22:587-93.
22. Clark RA, Lipworth BJ. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 1996;41:247-9.
23. Rhodes DG, Newton R, Butler R, Herbette L. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers. Mol Pharmacol 1992;42:596-602.
24. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 1994; 7:569-78.